MCID: ANP009
MIFTS: 43

Anaplastic Oligodendroglioma

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Anaplastic Oligodendroglioma

MalaCards integrated aliases for Anaplastic Oligodendroglioma:

Name: Anaplastic Oligodendroglioma 52 58 54 17 71
Oligodendroglioma, Anaplastic 6

Characteristics:

Orphanet epidemiological data:

58
anaplastic oligodendroglioma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 72 C0334590
Orphanet 58 ORPHA251630
UMLS 71 C0334590

Summaries for Anaplastic Oligodendroglioma

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 251630 Definition A rare glial tumor characterized by a grade III oligodendroglial tumour with focal or diffuse anaplastic features. It typically occurs in the supratentorial white matter. Histologically, the cells are enlarged and epithelioid with pleomorphic and increased size nuclei, a vesicular chromatin pattern and prominent nucleoli. Most patients present with seizures . Visit the Orphanet disease page for more resources.

MalaCards based summary : Anaplastic Oligodendroglioma, also known as oligodendroglioma, anaplastic, is related to oligoastrocytoma and glioma, and has symptoms including seizures and headache. An important gene associated with Anaplastic Oligodendroglioma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), and among its related pathways/superpathways are DNA Damage and Neural Crest Differentiation. The drugs Donepezil and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and t cells, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Anaplastic oligodendroglioma is a neuroepithelial tumor which is believed to originate from... more...

Related Diseases for Anaplastic Oligodendroglioma

Diseases related to Anaplastic Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 103)
# Related Disease Score Top Affiliating Genes
1 oligoastrocytoma 31.1 MGMT IDH2
2 glioma 30.6 POT1 IDH2 CDKN2A
3 juvenile pilocytic astrocytoma 30.1 OLIG2 MGMT
4 mixed oligodendroglioma-astrocytoma 30.1 MGMT IDH2
5 mixed glioma 30.0 OLIG2 MGMT IDH2
6 brain glioma 29.8 MGMT IDH2
7 brain cancer 29.5 OLIG2 OLIG1 MGMT IDH2
8 glioma susceptibility 1 29.4 OLIG2 MGMT IDH2 CDKN2A
9 grade iii astrocytoma 29.0 OLIG2 OLIG1 MGMT IDH2 CDKN2A
10 oligodendroglioma 28.6 POT1 OLIG2 OLIG1 MGMT IDH2 CDKN2C
11 glial tumor 10.6
12 glioblastoma multiforme 10.6
13 anaplastic oligoastrocytoma 10.6
14 astrocytoma 10.5
15 malignant glioma 10.5
16 arteriovenous malformation 10.2
17 parkinson disease, late-onset 10.1
18 leukemia, acute lymphoblastic 10.1
19 hydrocephalus 10.1
20 neutropenia 10.1
21 central neurocytoma 10.1
22 gangliocytoma 10.1
23 ganglioglioma 10.1
24 back pain 10.1
25 adult oligodendroglioma 10.1 OLIG2 IDH2
26 adult brain stem glioma 10.1 MGMT IDH2
27 gemistocytic astrocytoma 10.1 MGMT IDH2
28 adult astrocytic tumour 10.0 IDH2 CDKN2A
29 cerebral cavernous malformations 10.0
30 endosteal hyperostosis, autosomal dominant 10.0
31 li-fraumeni syndrome 10.0
32 williams-beuren syndrome 10.0
33 lymphoma, hodgkin, classic 10.0
34 myeloma, multiple 10.0
35 lymphoma, non-hodgkin, familial 10.0
36 meningioma, radiation-induced 10.0
37 meningioma, familial 10.0
38 psoriatic arthritis 10.0
39 li-fraumeni syndrome 2 10.0
40 lymphoma 10.0
41 childhood acute lymphocytic leukemia 10.0
42 lymphoblastic lymphoma 10.0
43 hepatic veno-occlusive disease 10.0
44 disseminated intravascular coagulation 10.0
45 pneumocystosis 10.0
46 spinal meningioma 10.0
47 leukemia 10.0
48 pancytopenia 10.0
49 acute leukemia 10.0
50 thrombocytopenia 10.0

Graphical network of the top 20 diseases related to Anaplastic Oligodendroglioma:



Diseases related to Anaplastic Oligodendroglioma

Symptoms & Phenotypes for Anaplastic Oligodendroglioma

UMLS symptoms related to Anaplastic Oligodendroglioma:


seizures, headache

GenomeRNAi Phenotypes related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.28 CDKN2A CDKN2C POT1
2 Decreased viability GR00221-A-3 9.28 CDKN2A POT1
3 Decreased viability GR00221-A-4 9.28 CDKN2A POT1
4 Decreased viability GR00249-S 9.28 CDKN2C
5 Decreased viability GR00301-A 9.28 CDKN2C

MGI Mouse Phenotypes related to Anaplastic Oligodendroglioma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.55 CDKN2A CDKN2C IDH2 MGMT OLIG2
2 no phenotypic analysis MP:0003012 9.26 CDKN2A MGMT OLIG2 POT1
3 respiratory system MP:0005388 8.92 CDKN2A CDKN2C MGMT OLIG2

Drugs & Therapeutics for Anaplastic Oligodendroglioma

Drugs for Anaplastic Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 257)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 3 120014-06-4 3152
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
4
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
5
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
6
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
7
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
8
Histamine Approved, Investigational Phase 3 51-45-6 774
9
Cyproheptadine Approved Phase 3 129-03-3 2913
10 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
11 Anesthetics Phase 3
12 Analgesics Phase 3
13 Cholinesterase Inhibitors Phase 3
14 Cholinergic Agents Phase 3
15 Liver Extracts Phase 3
16 Cola Phase 3
17 Narcotics Phase 3
18 Analgesics, Opioid Phase 3
19 Anesthetics, General Phase 3
20 Anesthetics, Intravenous Phase 3
21 Tubulin Modulators Phase 3
22 Antimitotic Agents Phase 3
23 Alkylating Agents Phase 3
24 Neurotransmitter Agents Phase 3
25 Central Nervous System Stimulants Phase 3
26 Dopamine Agents Phase 3
27 Dexmethylphenidate Hydrochloride Phase 3
28 Histamine Antagonists Phase 3
29 Anti-Allergic Agents Phase 3
30
Histamine Phosphate Phase 3 51-74-1 65513
31 Histamine H1 Antagonists Phase 3
32 Gastrointestinal Agents Phase 3
33
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
34
Ethanol Approved Phase 1, Phase 2 64-17-5 702
35
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
36
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
37
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
38
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
39
Bevacizumab Approved, Investigational Phase 2 216974-75-3
40
Phenobarbital Approved, Investigational Phase 1, Phase 2 50-06-6 4763
41
Phenytoin Approved, Vet_approved Phase 1, Phase 2 57-41-0 1775
42
Oxcarbazepine Approved Phase 1, Phase 2 28721-07-5 34312
43
Carbamazepine Approved, Investigational Phase 1, Phase 2 298-46-4 2554
44
Primidone Approved, Vet_approved Phase 1, Phase 2 125-33-7 4909
45
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
46
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
47
Mercaptopurine Approved Phase 2 50-44-2 667490
48
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
49
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
50
Panobinostat Approved, Investigational Phase 1, Phase 2 404950-80-7 6918837

Interventional clinical trials:

(show top 50) (show all 174)
# Name Status NCT ID Phase Drugs
1 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
2 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
3 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
4 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
6 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. Active, not recruiting NCT00626990 Phase 3 temozolomide
7 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
8 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
9 Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
10 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
11 A Phase II Study of Temozolomide in the Treatment of Recurrent Malignant Gliomas Unknown status NCT00004204 Phase 2 temozolomide
12 Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
13 Pilot Study to Determine Therapeutic Response of Oral Capecitabine (Xeloda) in Recurrent High Grade Gliomas (HGGs) by Establishing the Radiographic Response Rate Using Modified Macdonald Criteria Completed NCT00717197 Phase 2 Capecitabine
14 Phase II Trial of Bevacizumab Plus Erlotinib for Patients With Recurrent Malignant Glioma Completed NCT00671970 Phase 2 Bevacizumab and Erlotinib
15 Phase II Treatment of Adults With Newly Diagnosed, Progressive or Recurrent Primary Malignant Anaplastic Oligodendroglioma With Temodal Completed NCT00003465 Phase 2 temozolomide
16 The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
17 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Pure and Mixed Anaplastic Oligodendroglioma Completed NCT00400816 Phase 2 temozolomide
18 Open Label Phase II Study On STI571 (Glivec) Administered As A Daily Oral Treatment In Gliomas Completed NCT00039364 Phase 2 imatinib mesylate
19 A Phase II Study of Topotecan in Patients With Anaplastic Oligodendroglioma or Anaplastic Mixed Oligoastrocytoma Completed NCT00003372 Phase 2 topotecan hydrochloride
20 Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma Completed NCT00006080 Phase 2 fenretinide
21 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
22 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin
23 A Phase I/II Study of Col-3 Administered on a Continuous Daily Oral Schedule in Patients With Recurrent High-Grade Astrocytoma Completed NCT00004147 Phase 1, Phase 2 incyclinide
24 A Phase I/II Trial Of MGI114 For Treatment Of Patients With Recurrent Malignant Gliomas Completed NCT00012038 Phase 1, Phase 2 irofulven
25 A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
26 A Phase II Study of Temozolomide (SCH 52365, Temodal(R)) for the Treatment of Recurrent Malignant Glioma Completed NCT00004113 Phase 2 temozolomide
27 A Multi-Center, Open-Label Clinical Study to Evaluate the Safety and Performance of the Proxima GliaSite RTS, a Radiation Delivery System, in Patients With Recurrent Malignant Brain Tumors Undergoing Surgical Resection Completed NCT00003574 Phase 2
28 ANALYSIS OF THE EFFICACY OF SURAMIN IN RECURRENT MALIGNANT PRIMARY BRAIN TUMORS Completed NCT00002639 Phase 2 chemotherapy;suramin
29 A Phase II Trial of Poly ICLC in Patients With Recurrent Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
30 Bevacizumab in Combination With Irinotecan for Malignant Gliomas Completed NCT00268359 Phase 2 irinotecan hydrochloride
31 A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
32 Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma Completed NCT00859222 Phase 1, Phase 2 LBH589;bevacizumab
33 A Phase II Trial Of Thalidomide And Procarbazine In Adults With Recurrent/Progressive Gliomas Completed NCT00079092 Phase 2 procarbazine hydrochloride;thalidomide
34 A Phase I/II Trial of EMD 121974 for Treatment of Patients With Recurrent Anaplastic Gliomas Completed NCT00006093 Phase 1, Phase 2 cilengitide
35 A Phase I/II Study of Oral Procarbazine in the Treatment of Recurrent High Grade Astrocytomas Completed NCT00004004 Phase 1, Phase 2 procarbazine hydrochloride
36 A Phase II Trial Of Pre-Irradiation And Concurrent Temozolomide In Patients With Newly Diagnosed Anaplastic Oligodendrogliomas And Mixed Anaplastic Oligoastrocytomas Completed NCT00033280 Phase 2 temozolomide
37 Phase II Study of Antineoplastons A10 and AS2-1 in Children With Brain Tumors Completed NCT00003458 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
38 PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS Completed NCT00002752 Phase 1, Phase 2
39 A Phase II Trial Of Talampanel In Patients With Recurrent High-Grade Gliomas Completed NCT00064363 Phase 2 talampanel
40 Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00049127 Phase 1, Phase 2 Imatinib Mesylate
41 Trial Of Oral Thalidomide, Celecoxib, Etoposide And Cyclophosphamide In Adult Patients With Relapsed Or Progressive Malignant Gliomas Completed NCT00047281 Phase 2 celecoxib;cyclophosphamide;etoposide;thalidomide
42 Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study. Completed NCT00629889 Phase 2 levetiracetam;pregabalin
43 Improved Characterization of Brain Tumors By MRI and MRS Completed NCT00274755 Phase 2 chemotherapy
44 Phase II Study of Bevacizumab (Avastin) and BCNU for Treatment of Relapsed, High Grade Gliomas Completed NCT00795665 Phase 2 bevacizumab;carmustine
45 A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging Completed NCT00565721 Phase 2 Fluciclatide Injection - (AH111585 (F18))
46 A Pilot Study of Tamoxifen, Carboplatin and Topotecan in the Treatment of Recurrent or Refractory Primary Brain or Spinal Cord Tumors or Metastatic Epithelial Cancers With Central Nervous System Metastases Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
47 Dynamic Contrast-Enhanced Magnetic Resonance Imaging With Bevacizumab in Combination With Irinotecan for Malignant Gliomas Completed NCT00352521 Phase 2 bevacizumab;irinotecan
48 A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue Completed NCT01032200 Phase 2 Armodafinil
49 Oral ST1481 in Adults With Malignant Glioma: A Phase I-II Clinical Trial Completed NCT00087061 Phase 1, Phase 2 gimatecan
50 CAMP 004A - Phase 2 Study Of Intensive Chemotherapy (BET) For Selected Categories Of Malignant Central Nervous System Tumor Completed NCT00007982 Phase 2 carmustine;cisplatin;cyclophosphamide;etoposide;thiotepa

Search NIH Clinical Center for Anaplastic Oligodendroglioma

Genetic Tests for Anaplastic Oligodendroglioma

Anatomical Context for Anaplastic Oligodendroglioma

MalaCards organs/tissues related to Anaplastic Oligodendroglioma:

40
Brain, Spinal Cord, T Cells, Breast, Bone, Bone Marrow, Eye

Publications for Anaplastic Oligodendroglioma

Articles related to Anaplastic Oligodendroglioma:

(show top 50) (show all 577)
# Title Authors PMID Year
1
IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. 61 54
19805356 2009
2
[Temozolomide: Temodal]. 54 61
18347414 2008
3
Serum GFAP is a diagnostic marker for glioblastoma multiforme. 54 61
17998256 2007
4
The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. 54 61
17440165 2007
5
Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization. 54 61
17319279 2007
6
[Expression of epidermal growth factor receptor and PTEN in malignancy brain tumors]. 61 54
17236582 2006
7
Malignant glioma: neuropathology and neurobiology. 61 54
16944363 2006
8
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. 54 61
15455350 2005
9
PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. 61 54
11438483 2001
10
Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. 54 61
11307615 2001
11
Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. 61 54
10515227 1999
12
Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. 61 54
10485462 1999
13
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. 61 54
9776413 1998
14
Epidermal growth factor receptor expression in oligodendroglial tumors. 61 54
8686753 1996
15
Lectins: reliable differentiation markers in human oligodendrogliomas. 54 61
8220777 1993
16
Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network. 61
31561286 2020
17
5-ALA False-Positive in Anaplastic Oligodendroglioma, IDH-mutant and 1p/19q-codeleted. 61
32243563 2020
18
Role of the default mode resting-state network for cognitive functioning in malignant glioma patients following multimodal treatment. 61
32540630 2020
19
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. 61
32293798 2020
20
Involvement of the Olfactory Apparatus by Gliomas. 61
32165363 2020
21
A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. 61
32169363 2020
22
Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas. 61
32324987 2020
23
A novel PTPRZ1-ETV1 fusion in gliomas. 61
31381204 2020
24
Spinal leptomeningeal oligodendrogliomatosis after resection of cerebral anaplastic oligodendoglioma with 1p19q Co-deletion - A case report. 61
32007374 2020
25
Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation. 61
31028406 2020
26
Prognostic Value of O-(2-[18F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III Glioma. 61
30977078 2019
27
High-grade Glioma Masquerading as a Small Cerebral Hemorrhage: A Case Report. 61
31849570 2019
28
Experience Profiling of Fluorescence-Guided Surgery I: Gliomas. 61
31686440 2019
29
The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01. 61
31686436 2019
30
Anaplastic Oligodendroglioma with Transdural Extension. 61
31254692 2019
31
Extent of resection and survival for oligodendroglioma: a U.S. population-based study. 61
31407129 2019
32
Reclassification of Mongolian Diffuse Gliomas According to the Revised 2016 World Health Organization Central Nervous System Tumor Classification. 61
31370384 2019
33
Scalp Metastasis of Anaplastic Oligodendroglioma. 61
31125773 2019
34
Incidence trends of adult malignant brain tumors in Finland, 1990-2016. 61
30985227 2019
35
[IDH、TERT and 1p/19q predicting clinical outcomes in patients with anaplastic oligodendroglioma]. 61
31269600 2019
36
Anaplastic oligodendroglioma metastasizing to the bone marrow: a unique case report and literature review. 61
30526175 2019
37
PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. 61
30975663 2019
38
Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control. 61
31141785 2019
39
c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas. 61
30878754 2019
40
Bone metastases from a 1p/19q codeleted and IDH1-mutant anaplastic oligodendroglioma: a case report. 61
31248444 2019
41
Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. 61
30677248 2019
42
Glioma Tumor Grade Identification Using Artificial Intelligent Techniques. 61
30900029 2019
43
Anaplastic Oligodendroglioma Found as an Incidental Photopenic Lesion on 18F-FP-CIT PET/CT Image. 61
30672761 2019
44
Sequencing of Chemotherapy and Radiotherapy for Newly Diagnosed Anaplastic Oligodendroglioma and Oligoastrocytoma. 61
30601146 2019
45
Determination of genetic aberrations and novel transcripts involved in the pathogenesis of oligodendroglioma using array comparative genomic hybridization and next generation sequencing. 61
30675227 2019
46
Navigated Transcranial Magnetic Stimulation in Patient with Cranioplasty in Situ: Safe and Accurate Procedure. 61
30296623 2019
47
Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics. 61
30738431 2019
48
Radiomics-Based Machine Learning Technology Enables Better Differentiation Between Glioblastoma and Anaplastic Oligodendroglioma. 61
31750250 2019
49
Glioma Simultaneously Present with Adjacent Meningioma: Case Report and Literature Review. 61
30937052 2019
50
Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma. 61
31386006 2019

Variations for Anaplastic Oligodendroglioma

ClinVar genetic disease variations for Anaplastic Oligodendroglioma:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CIC NM_015125.4(CIC):c.643C>T (p.Arg215Trp)SNV Likely pathogenic 635170 rs1568504941 19:42791757-42791757 19:42287605-42287605

Expression for Anaplastic Oligodendroglioma

Search GEO for disease gene expression data for Anaplastic Oligodendroglioma.

Pathways for Anaplastic Oligodendroglioma

Pathways related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.6 MGMT CDKN2C CDKN2A
2 11.27 OLIG2 OLIG1
3 11.05 OLIG2 OLIG1
4 10.13 CDKN2C CDKN2A

GO Terms for Anaplastic Oligodendroglioma

Biological processes related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G1/S transition of mitotic cell cycle GO:0000082 9.37 CDKN2C CDKN2A
2 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.32 CDKN2C CDKN2A
3 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.26 CDKN2C CDKN2A
4 neuron fate commitment GO:0048663 9.16 OLIG2 OLIG1
5 negative regulation of phosphorylation GO:0042326 8.96 CDKN2C CDKN2A
6 oligodendrocyte differentiation GO:0048709 8.8 OLIG2 OLIG1 CDKN2C

Molecular functions related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.35 POT1 OLIG2 OLIG1 MGMT CDKN2A
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CDKN2C CDKN2A

Sources for Anaplastic Oligodendroglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....